Search the Newsreel

ClearPoint Neuro (NASDAQ:CLPT) Downgraded to "Strong Sell" Rating by Wall Street Zen

Wall Street Zen has downgraded ClearPoint Neuro (NASDAQ:CLPT) to a "strong sell" rating, despite other analysts having a mixed view with a consensus "Hold" rating and a target price of $25.67. The downgrade follows ClearPoint Neuro missing its quarterly earnings expectations, reporting an adjusted …

Clearpoint Neuro Inc (CLPT) Earnings Forecast: Future EPS & Revenue Growth Estimates

Clearpoint Neuro Inc (CLPT) Stock News Today

ClearPoint Neuro, Inc. (NASDAQ:CLPT) Just Reported And Analysts Have Been Cutting Their Estimates

ClearPoint Neuro, Inc. (NASDAQ:CLPT) recently missed its second-quarter earnings expectations, with revenues 15% below forecasts and statutory losses increasing significantly. This has led analysts to downgrade revenue estimates for 2026 and project higher per-share losses, resulting in a 9.4% reduction in the consensus price …

Analysts Have Lowered Expectations For ClearPoint Neuro, Inc. (NASDAQ:CLPT) After Its Latest Results

ClearPoint Neuro, Inc. (NASDAQ:CLPT) recently released its latest quarterly results, leading analysts to significantly reduce their earnings forecasts for the company. Despite the downward revisions, the consensus price target remains largely unchanged at US$17.17, suggesting that analysts still see potential for share price appreciation. …

ClearPoint Neuro (CLPT) Stock Sinks As Cash Burn Deepens

ClearPoint Neuro (CLPT) investors disclose 7.45% beneficial ownership stake

An amended Schedule 13G filing reveals that investors led by Bigger Capital Fund, LP have disclosed a beneficial ownership stake of 7.45% in ClearPoint Neuro (CLPT). Michael Bigger, through various affiliations and personal holdings, is deemed to beneficially own 2,272,980 shares of the common …

Stifel cuts Clearpoint Neuro stock price target on guidance cut

Stifel lowered its price target for Clearpoint Neuro (NASDAQ:CLPT) from $25 to $22, while maintaining a Buy rating, following the company's guidance cut. Clearpoint Neuro reported second-quarter revenue of $10.9 million, missing estimates, and reduced its 2026 revenue guidance by 7% to $50 million. …

ClearPoint Neuro (CLPT) Reports Q2 Earnings: What Key Metrics Have to Say

ClearPoint Neuro (CLPT) reported Q2 2026 revenue of $10.88 million, an 18% increase year-over-year, but missed the Zacks Consensus Estimate of $13 million. The company posted an EPS of -$0.38, also missing the consensus estimate of -$0.29. Key metric analysis revealed varied performance across …

Clearpoint Neuro Inc reports results for the quarter ended June 30 - Earnings Summary

Clearpoint Neuro Inc. has released its earnings summary for the quarter that ended on June 30. The article, provided by Refinitiv, gives an overview of the company's financial performance during this period.

ClearPoint Neuro outlines $48M-$52M 2026 revenue guidance as it prioritizes CAL, clinical capacity, and focused ultrasound partnership

Earnings Call Insights: ClearPoint Neuro (CLPT) Q2 2026 MANAGEMENT VIEW * "The second quarter of 2026 in itself has been an exciting one and possibly one of the most important series of events in our history," said Joseph Burnett (President, CEO & Director), adding …

ClearPoint Neuro (Nasdaq: CLPT) grows Q2 revenue and updates 2026 outlook

ClearPoint Neuro (CLPT) reported strong Q2 2026 revenue of $10.9 million, an 18% increase year-over-year, driven by significant growth in neurosurgery navigation and therapy. The company has updated its 2026 revenue guidance to between $48.0 million and $52.0 million, reflecting strategic investments in clinical …

ClearPoint Neuro, Inc. (CLPT) Reports Q2 Loss, Misses Revenue Estimates

ClearPoint Neuro, Inc. (CLPT) reported a Q2 loss of $0.38 per share, missing the Zacks Consensus Estimate of a $0.29 loss, and revenues of $10.88 million, falling short of estimates by 16.31%. The company's shares have gained 9.2% year-to-date, slightly underperforming the S&P 500. …

ClearPoint Neuro Q2 Earnings Call Highlights

ClearPoint Neuro (CLPT) reported an 18% revenue growth in Q2 2026, reaching $10.9 million, and adjusted its full-year guidance to $48-$52 million. The company is shifting investment priorities towards clinical capacity, preclinical laboratory services, and neuro drug delivery technologies, with increased spending in R&D, …

ClearPoint Neuro, Inc. (CLPT) Q2 2026 Earnings

ClearPoint Neuro, Inc. (CLPT) reported its Q2 2026 earnings, missing analyst expectations for both EPS and revenue. The company's cash reserves decreased, and it lowered its full-year 2026 revenue guidance to $48 million to $52 million. This performance is attributed to a pivot towards …

ClearPoint Neuro Reports Second Quarter 2026 Results

ClearPoint Neuro, Inc. announced its second-quarter 2026 financial results, reporting $10.9 million in revenue, an 18% increase year-over-year, driven by the IRRA flow Portfolio acquisition and growth in neurosurgery navigation. While Biologics and Drug Delivery revenue saw a decline, the company expects a rebound …

(CLPT) as a Liquidity Pulse for Institutional Tactics

Clearpoint Neuro, Inc. (NASDAQ: CLPT) is experiencing strong near-term sentiment that is challenging persistent mid and long-term weakness. The article details institutional trading strategies including position, momentum breakout, and risk hedging, alongside multi-timeframe signal analysis, indicating potential resistance and support levels. An exceptional 117.8:1 …

ClearPoint Neuro (NASDAQ:CLPT) Issues Quarterly Earnings Results, Misses Estimates By $0.09 EPS

ClearPoint Neuro (Nasdaq: CLPT) lifts Q2 2026 revenue while net loss deepens

Aspen's Parkinson's Cell Therapy Gets FDA RMAT Designation—Not Approval

ClearPoint Neuro announced that its partner Aspen Neuroscience received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for sasineprocel, an investigational Parkinson's disease therapy. This designation expedites development and review but does not constitute FDA approval. ClearPoint Neuro's Navigation System and SmartFlow Cannula are utilized …

ClearPoint Neuro Congratulates Partner Aspen Neuroscience on FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Sasineprocel

ClearPoint Neuro congratulates its partner Aspen Neuroscience on receiving the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation for sasineprocel (ANPD001), an investigational autologous cell replacement therapy for Parkinson's disease. This designation will support an expedited development and review pathway for Aspen's therapy, which utilizes …

Clearpoint Neuro Inc (CLPT) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Clearpoint Neuro Inc (CLPT) as of July 31, 2026. The company's valuation score is 7.11, placing it 142nd out of 199 in the Healthcare Equipment & Supplies industry. The article highlights CLPT's current P/E ratio of -14.82 …

Clearpoint Neuro Inc (CLPT) Institutional Confidence

Clearpoint Neuro Inc (CLPT) has an institutional shareholding score of 5.00, ranking 107th in the Healthcare Equipment & Supplies industry. Institutional ownership increased by 23.25% quarter-over-quarter, with 52.78% of shares held by institutions. The largest institutional shareholder, Bill Nygren | OAKMX, holds 124.35K shares, …

CLPT|Clearpoint Neuro Inc|Price:14.813|Chg%:+0.693

This article provides a detailed company profile for Clearpoint Neuro Inc (CLPT), a medical device company specializing in precise navigation for brain and spine procedures. It outlines the company's business scope, including its ClearPoint Neuro Navigation System and ClearPoint Prism Neuro Laser Therapy System, …

Clearpoint Neuro Inc (CLPT) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Clearpoint Neuro Inc (CLPT) focusing on its dividend and stock split history. It notes that the company has distributed $0.00 in dividends over the past five years. The page displays current stock information including its market cap and …

Clearpoint Neuro Inc (CLPT) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Clearpoint Neuro Inc (CLPT), listing major institutional holders and their proportion of shares. It also provides a breakdown of shareholder types such as investment advisors, hedge funds, and corporations. The report includes institutional shareholding trends over several …

Clearpoint Neuro Inc (CLPT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Clearpoint Neuro Inc (CLPT) by business segment and region. The data, updated April 6, shows that in the most recent fiscal year (FY2025), products related to functional neurosurgery contributed 40.12% of revenue, followed by services for biologics …

CLPT|Clearpoint Neuro Inc|Price:14.120|Chg%:-0.370

TradingKey provides a comprehensive stock analysis of Clearpoint Neuro Inc (CLPT), highlighting its strong fundamentals, high growth potential, and "fairly valued" status within the Healthcare Equipment & Supplies industry. The analysis notes high institutional ownership and multiple "Buy" ratings from analysts, with a highest …

(CLPT) Risk Channels and Responsive Allocation

Clearpoint Neuro, Inc. (NASDAQ: CLPT) is showing weak near and mid-term sentiment, despite a neutral long-term outlook. An exceptional 149.0:1 risk-reward setup is identified, targeting a 44.8% gain versus 0.3% risk. The article outlines specific institutional trading strategies, including long, breakout, and short positions, …

ClearPoint Neuro Q2 review starts Aug. 3 at 4:30 p.m. ET

ClearPoint Neuro (NASDAQ: CLPT) announced it will release its second quarter 2026 financial results on Monday, August 3, 2026, after the market closes. The company will also host a live earnings conference call and webcast at 4:30 p.m. Eastern time on the same day …

ClearPoint Neuro to Announce Second Quarter 2026 Results August 3, 2026

ClearPoint Neuro, Inc. will release its financial results for the second quarter of 2026 on Monday, August 3rd, after the market closes. Investors and analysts are invited to a live broadcast review and conference call at 4:30 p.m. Eastern time on the same day. …

CLPT Forecast — Price Target — Prediction for 2027

ClearPoint Neuro: AMT-130's FDA Reversal Revives The Bull Case (NASDAQ:CLPT)